Neuren Pharmaceuticals Limited (AU:NEU) has released an update.
Neuren Pharmaceuticals reports a significant increase in H1 2024 royalty income to A$24.3 million, an upsurge from A$3.5 million in H1 2023, with a profit after tax of A$8.0 million. The company’s cash and short-term investments stand at A$213 million, reflecting a strong financial position. Neuren also anticipates robust full-year revenue from DAYBUE™ of A$132-138 million, highlighting successful Phase 2 trials of NNZ-2591 for treating neurodevelopmental disorders.
For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.
